Antiviral Drugs Market Projected to Reach USD 89.68 Billion by 2033 at a 3.9% of CAGR

The antiviral drugs market is anticipated to experience significant growth, flourishing at an average CAGR of 3.9% between 2023 and 2033. The market is expected to achieve a valuation of USD 61.42 billion in 2023 and is projected to hold a market share of USD 89.68 billion by 2033.

This robust growth in the antiviral drugs market is driven by the increasing prevalence of viral infections and the ongoing demand for effective antiviral treatments. As healthcare providers and patients alike seek innovative solutions to combat viral diseases, the market for antiviral medications is positioned for expansion.

The development of new antiviral drugs, coupled with advancements in research and technology, is expected to bolster the market’s growth. Additionally, the rise in public awareness regarding viral infections and preventive healthcare measures will further contribute to the demand for antiviral treatments.

Industry stakeholders are encouraged to remain informed about emerging trends and developments in the antiviral drugs market, as these innovations will play a crucial role in enhancing patient care and improving health outcomes globally.

The global anti-viral drugs market is projected to register a moderate growth rate in the pharmaceutical market and which is anticipated to increase due to rise in awareness level, increase in the diseased population and introduction of new drugs with improved efficacy.

Some major patents are reaching their expiry during forecast period, such as for Combivir, Sustiva, Tenofovir, Tamiflu, Relenza and Telbivudine. The patent expiries of these blockbuster drugs is expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.

The late stage pipeline drugs are expected to enter the market, which will positively impact the market. Most antivirals are considered comparatively harmless to host, and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles, either outside or inside the body.

The anti-viral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses and the hepatitis B and C viruses.

Anti-viral Drugs Market: Drivers and Restraints

As of October 2013, according to WHO, there were around 35.3 Mn people globally, infected with HIV. Therefore, increased viral infection incidences is one of the important factors that drives the anti-viral drugs market growth. Because of the solid R&D activities, newer and advanced treatments and formulations, such as vaccines, combination therapy and others, are being introduced in the market.

Hence, strong R&D is one of the crucial factors in the anti-viral drugs market growth. On the other hand, high risk of failure, high cost of R&D and therapy, and government austerity are some of threats expected to hinder the growth of market.

These are some factors anticipated to fuel growth of global anti-viral drugs market within the forecast period of 2016-2026. However, increasing usage of natural products and high cost of developing drugs are the key challenges faced by the market.

Anti-viral Drugs Market: Overview

The generic market of anti-viral drugs is presently dominated by products such as didanosine, zidovudine, lamivudine and stavudine. The biggest driver of overall anti-viral drugs market is Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for more than half the share of the market 2010.

At the end of 2012, 9.7 million people in low-income and middle-income countries were on antiretroviral treatment (ART). According to WHO, in 2012, number of patients on ART increased by 1.6 Mn, the largest increase in one year.

Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.

A Full Report Overview

Anti-viral Drugs Market: Regional Overview

Region wise, the global anti-viral drugs market is classified into regions namely, North America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. In 2015, in India the number of people living with HIV were 2.1 Mn and in U.S. the number was around 1.2 Mn in the year 2013.

Anti-viral Drugs Market: Key Players

Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.

Key Segments Covered in the Anti-Viral Drugs Industry Analysis

Anti-Viral Drugs Market by Product type:

• Hepatitis-C antivirals
• HIV antivirals
• Herpes antivirals
• Hepatitis-B antivirals
• Influenza antivirals
• Others (Pneumonia, Flu, etc.)

Anti-Viral Drugs Market by End-user:

• Hospitals
• Clinics
• Ambulatory Surgical Centers

Anti-Viral Drugs Market by Region:

• North America Anti-Viral Drugs Market
• Latin America Anti-Viral Drugs Market
• Europe Anti-Viral Drugs Market
• Asia Pacific Anti-Viral Drugs Market
• The Middle East & Africa Anti-Viral Drugs Market

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube